The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Open accessAbstract
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF levels of Aβ and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neurodegenerative pathology, but more disease specific information can be gleaned from assessment of the specific post-translational modifications of tau [37,59].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 4×
“…biomarker compared with its measurement in CSF. Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with accuracy change on Aβ42/40 ratio detected in CSF and associates with measures of brain amyloid plaques by amyloid PET scans (Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).”
BackgroundMethodInfluentialSelf-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Cited by
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
“42,53 Findings of a large, multi centre cohort study showed that plasma pTau217 can differentiate Alzheimer’s disease from non-Alzheimer’s disease dementias with high accuracy (96%), similar to the performance of established CSF or tau-PET biomarkers.”
InfluentialPost-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“At present, only a limited number of approved blood-based assays are available to clinicians to detect AD pathology (88); however, several novel assays are currently under investigation, including those measuring various phosphorylated forms of tau, including p-tau181 and p-tau217 (89).”
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Alzheimer’s disease drug development pipeline: 2022
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665
“4 Nearly all the participants meeting the tau PET criteria had positive amyloid imaging; the discordance was 0.9% of individuals who met the tau PET criteria and not the amyloid PETcriteria.”
MethodInfluential
Metadata
- Authors
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Barthélemy, Nicolas R.
- Bateman, Randall J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-28
- Volume
- 217
- Issue
- 11
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7596823
- OpenAlex
- W3045987239
- Cited by
- 437
- References
- 36
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alzheimer’s Association (AARF-16-443265)
- Rainwater Charitable Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- Tau SILK Consortium
- AbbVie
- Biogen
- Eli Lilly and Company
- Coins for Alzheimer’s Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. https://app.cochat.ai/papers/10.1084/jem.20200861
- The paper
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020). Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20200861
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.